Associated Papers
RBM10 Mutation as a Potential Negative Prognostic/Predictive Biomarker to Therapy in Non-Small-Cell Lung Cancer.
Reyes A et al.
Clinical Lung Cancer, 2024
Simulation analysis of EGFR mutation detection: Oncomine Dx target test and AmoyDx panel impact on lung cancer treatment decisions.
Hirotsu Y et al.
Scientific Reports, 2024
38238401 (PubMed )
Supplement: 41598_2024_52006_MOESM1_ESM.xlsx › Supplementary_Table_all_list
Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Du Z et al.
Biomolecules, 2023
36830579 (PubMed )
Supplement: biomolecules-13-00210-s001.zip › biomolecules-2098784-supplementary.xlsx › Table_S8
NOS3 and CTH gene mutations as new molecular markers for detection of lung adenocarcinoma.
Abdullah Ramadhan I et al.
Peerj, 2023
38107574 (PubMed )
Supplement: peerj-11-16209-s002.xls › NOS3
Next-generation sequencing in advanced Chinese melanoma reveals therapeutic targets and prognostic biomarkers for immunotherapy.
Huang F et al.
Scientific Reports, 2022
35688842 (PubMed )
Supplement: 41598_2022_13391_MOESM5_ESM.xlsx › NGS_data
Select a paper to view details